title: Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study.
abstract: OBJECTIVE
  To determine the effect of multiple injections of ranibizumab or bevacizumab on retinal nerve fiber layer (RNFL) and intraocular pressure (IOP) in patients with age-related macular degeneration (AMD).
  
  
  METHODS
  This retrospective study includes 35 eyes of 35 patients treated with intravitreal bevacizumab (IVB, 1.25mg/0.05mL) and 30 eyes of 30 patients with intravitreal ranibizumab (IVR, 0.5mg/0.05mL) who had Fast RNFL analysis (Stratus™); IOP measurements were taken 30 minutes and 24 hours after each injection.
  
  
  RESULTS
  The mean ages were 68.0±7.5 and 69.1±7.7 years in the IVR and IVB groups, respectively (P=0.55). They underwent (6.3±1.9) and (5.1±1.3) injections (P=0.07) over (13.6±2.1) and (14.05±2.6) months (P=0.45) in the IVR and IVB groups, respectively. Changes in overall and temporal RNFL thickness in IVR-treated eyes (105.3±6.9µm and 74.4±11.2µm) were not different from those in untreated eyes in the IVR group (104.6± 8.4µm and 75.1±12.6µm) (P=0.57 and P=0.41, respectively). Similarly, overall and temporal RNFL thickness in IVB-treated eyes (105.8±8.1µm and 74.5±11.8µm) were not different from those in untreated eyes in the IVB group (104.6±8µm and 74.8±12.9µm) (P=0.42 and P=0.80, respectively). The frequencies of IOP rise (P=0.60) and changes in RNFL thickness from baseline (P=0.16) were comparable between groups.
  
  
  CONCLUSIONS
  Repeated intravitreal injection of ranibizumab or bevacizumab does not seem have adverse effects on RNFL thickness or IOP in wet AMD patients.
authors: Department of Ophthalmology, GATA Medical School, Ankara, Turkey.
authors: Güngör
authors: G
authors: Sobacı
authors: Rıza
authors: R
authors: Güngör
authors: Gökhan
authors: G
authors: Ozge
keywords: adverse effect; anti-VEGF; bevacizumab; intraocular pressure; ranibizumab; retinal nerve fiber layer
references: Eur J Ophthalmol. 2010 Nov-Dec;20(6):1076-8
references: 20954148
references: J Glaucoma. 2009 Mar;18(3):213-6
references: 19295375
references: Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):955-8
references: 18425523
references: Retina. 2009 Oct;29(9):1346-55
references: 19934825
references: J Glaucoma. 2012 Apr-May;21(4):241-7
references: 21423038
references: Am J Ophthalmol. 2008 Dec;146(6):930-4.e1
references: 18775528
references: J Ocul Pharmacol Ther. 2010 Feb;26(1):105-10
references: 20187807
references: Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1707-10
references: 19916212
references: Retina. 2007 Oct;27(8):1044-7
references: 18040242
references: Can J Ophthalmol. 2007 Dec;42(6):807-11
references: 18026202
references: Ophthalmic Surg Lasers Imaging. 2009 May-Jun;40(3):293-5
references: 19485295
references: Retina. 2004 Oct;24(5 Suppl):S3-19
references: 15483476
references: N Engl J Med. 2011 May 19;364(20):1897-908
references: 21526923
references: Open Ophthalmol J. 2010 Jun 22;4:28-9
references: 20871754
references: J Glaucoma. 2001 Jun;10(3):163-9
references: 11442177
references: Br J Ophthalmol. 2011 Aug;95(8):1111-4
references: 20702430
references: Retina. 2010 Apr;30(4):671-81
references: 19952984
references: Eye (Lond). 2011 Jun;25(6):661-72
references: 21455242
references: Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3438-46
references: 19255151
references: Retina. 2006 Mar;26(3):270-4
references: 16508425
references: Am J Ophthalmol. 2010 Oct;150(4):558-561.e1
references: 20643396
references: Am J Ophthalmol. 2009 Jul;148(1):43-58.e1
references: 19376495
references: Eye (Lond). 2009 Jan;23(1):181-5
references: 17693999
references: Retina. 2009 Mar;29(3):313-8
references: 19287287
references: Am J Pathol. 2007 Jul;171(1):53-67
references: 17591953
references: Curr Opin Ophthalmol. 2010 May;21(3):218-26
references: 20393293
references: Retina. 2009 Mar;29(3):306-12
references: 19060776
references: Curr Opin Ophthalmol. 2009 May;20(3):223-5
references: 19367163